Sage Journals: Discover world-class research

Abstract

Objective

Papillary thyroid carcinoma (PTC) accounts for 95% of all thyroid carcinomas. PTC is an epithelial tumor characterized by the proliferation of follicular cells with distinctive nuclear features, and is heterogeneous in terms of its carcinogenesis and behavior. PTC has been associated with several genetic abnormalities, of which the BRAF V600E mutation is the most common. However, reported incidences of this mutation have varied depending on the patient background, population size, or methods. In this study, we investigated the incidence of BRAF V600E mutation and its relationships with clinicopathological characteristics in patients with PTC.

Methods

Surgical specimens were obtained from 40 patients with PTC who underwent surgery at Nippon Medical School Hospital between 2009 and 2017. DNA from exon 15 of the BRAF gene was extracted and amplified by polymerase chain reaction, followed by direct sequencing.

Results

The frequency of BRAF V600E mutation increased with age. However, there were no correlations between BRAF V600E mutation and other clinicopathological features including sex, Hashimoto disease, family history of thyroid disease, tumor size, pathological T stage, pathological N stage, lymphovascular invasion, extrathyroidal extension, and metastasis.

Conclusions

This study demonstrated that PTCs harboring the BRAF V600E mutation increased in an age-dependent manner.

Keywords

Thyroid carcinoma papillary thyroid carcinoma mutation sequence clinicopathological feature

Introduction

Papillary thyroid carcinoma (PTC) is a major endocrine malignancy, with an increasing incidence in all age groups worldwide.¹ Knowledge of the genetic alterations in PTC has gradually improved in recent years, and the BRAF V600E mutation has been identified as the most common mutation.^2,3 BRAF mutation results in constitutive activation of the mitogen-activated protein kinase (MAPK) pathway, which in turn promotes cell growth, proliferation, and differentiation.

BRAF mutations were observed in 36% to 83% of cases of PTC in all age groups,⁴ and in 0% to 63% of pediatric cases.^1,5–11 However, the frequency varies and studies in pediatric patients are limited. BRAF mutation was previously reported to be associated with older male patients.^12–15 Many studies have suggested that BRAF mutation is related to aggressive features of PTCs, including large tumor size,^13,16–18 extrathyroidal extension,^15,18,19 vascular invasion,^12,20 lymph node metastasis,^5,12,20 advanced stage,^18,19,21 recurrence,¹⁷ and higher disease-specific mortality.^5,22 However, other studies have demonstrated different results,^23,24 indicating that these clinicopathological features can vary depending on the patient background and research methodology.^22,25 Given that BRAF is a potential molecular target in PTC, it is important to clarify the frequency and clinical significance of BRAF mutation in these patients.

The aim of this study was to investigate the frequency of BRAF mutation in adult and pediatric patients with PTC, and to examine the relationships between the mutation rate and clinicopathological features of PTCs in our institution.

Methods

Patients

Eligible patients were pathologically diagnosed with PTC following thyroid resection at the Department of Endocrine Surgery, Nippon Medical School Hospital, Tokyo, Japan, from 2009 to 2017. Because of the small amount of tumor tissue, tumors with extensive fibrosis, calcification, hematoma, or cystic lesions were excluded from the study, and 50 cases were finally selected for analysis. Clinical and pathological data were retrieved from the patients’ medical records. The tumors were staged according to the Union for International Cancer Control classification. This study was conducted according to the STROBE statement and written consent was obtained from all the patients for the use of the clinical samples for research purposes. This study was approved by the Ethics Committee of Nippon Medical School Hospital (No. 29-12-867, December 2017), and registered at the UMIN Clinical Trial Registry as UMIN00037461.

Genetic analysis

Tissues were obtained from the patients, fixed in formalin, and paraffin embedded (FFPE). Tumor tissue was then dissected manually from the representative tissue sections and total DNA was extracted using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA, USA) according to the manufacturer’s protocol. BRAF exon 15 was amplified by polymerase chain reaction (PCR) using the following primers: forward, 5’-CTTCATGAAGACCTCACAGTA-3’; reverse, 5’- TAGTTGAGACCTTCAATGACTT-3’. PCR was carried out using standard buffer conditions, 100 ng DNA, and AmpliTaq Gold DNA Polymerase (Thermo Fisher Scientific, Waltham, MA, USA) with 40 cycles of denaturing at 96°C for 60 seconds, annealing at 55°C for 60 seconds, and extension at 77°C for 60 seconds in a total volume of 50 µL. Two microliters of the purified PCR product was sequenced using a BigDye Terminator v3.1 Sequencing Kit (Applied Biosystems, Foster City, CA, USA) for 25 cycles using 1.0 pmol primers, with denaturing at 96°C for 10 seconds, annealing at 55°C for 5 seconds, and extension at 60°C for 1 minute. Sequences were determined using a semi-automated sequencer (ABI 3130 Genetic Analyzer, Applied Biosystems) and a sequence analyzer (Data Collection, version 3.0).

Statistical analysis

The relationship between the presence of BRAF V600E mutation and age was analyzed by χ² test and the relationship between mutation and tumor size by Mann–Whitney U test. The relationships between BRAF V600E mutation and all other clinicopathological features were analyzed by two-tailed Fisher’s exact tests. Statistical analysis was performed using SPSS version 25 (IBM Corp., Armonk, NY, USA). A value of P < 0.05 was considered significant.

Results

Clinical characteristics

DNA amplification was successful in 40 of the 50 cases, and these were therefore used for further analysis. The clinical characteristics of the 40 cases are summarized in Table 1. All patients were Asian and aged 13 to 79 years (average 31.8, median 24 years).

Table 1.

Clinical characteristics in all patients with papillary thyroid carcinoma.

	Age group (years)
	Total	13–19	20–39	40–59	60–79
	n = 40	n = 7	n = 24	n = 4	n = 5
Mean age [range], years	31 [13–79]	17 [13–19]	24 [23–34]	51 [43–54]	69 [61–79]
Sex (female/male)	37/3	7/0	23/1	2/2	5/0
Hashimoto disease, n (%)	12 (30)	2 (29)	7 (29)	1 (25)	2 (40)
Non-thyroid malignancy, n (%)	5 (12)	0	0	3 (75)	2 (40)
Family history of non-thyroid malignancy, n (%)	2 (5)	0	1 (4)	0	1 (20)
Family history of thyroid carcinoma, n (%)	3 (7.5)	1 (14)	1 (4)	1 (25)	0
Family history of benign thyroid disease, n (%)	4 (10)	2 (29)	1 (4)	0	1 (20)

Disease characteristics

The disease characteristics of the 40 analyzed patients are shown in Table 2. Tumor size did not significantly differ by age, but the minimum size was seen in patients aged 20 to 39 years and the maximum size in patients aged 13 to 19 years. There was a non-significant trend towards more advanced stage in patients aged 60 to 79 years compared with younger age groups. Thirty-four patients underwent lymph node dissection and six did not. Histologically, there were 38 cases (95%) of conventional PTC, one (2.5%) of cribriform variant (Figure 1a,b), and one (2.5%) of PTC with poorly differentiated components (Figure 1c,d). The follow-up duration was 1 to 96 months (average 26, median 21). No patients died from PTC and there was no recurrence or metastasis, except for one patient who had metastasis at their initial diagnosis.

Table 2.

Disease characteristics in all patients with papillary thyroid carcinoma.

	Age group (years)
	Total	13–19	20–39	40–59	60–79
	n = 40	n = 7	n = 24	n = 4	n = 5
Mean tumor size [range], cm	1.9 [0.5–7.0]	2.4 [0.7–7.0]	1.7 [0.5–4.0]	1.5 [0.6–2.2]	2.3 [1.4–3.5]
pT stage, n (%)
pT1a	10 (25)	1 (14)	8 (33)	1 (25)	0
pT1b	10 (25)	2 (29)	5 (21)	2 (50)	1 (20)
pT2	11 (28)	3 (43)	6 (25)	1 (25)	1 (20)
pT3a	1 (2.5)	0	1 (4)	0	0
pT3b	7 (17.5)	1 (14)	4 (17)	0	2 (40)
pT4a	1 (2.5)	0	0	0	1 (20)
pN stage, n (%)
pN0	10 (25)	0	8 (33)	1 (25)	1 (20)
pN1a	17 (42.5)	3 (7.5)	9 (23)	3 (75)	2 (40)
pN1b	7 (18)	1 (14)	5 (21)	0	1(20)
pNX	6 (15)	3 (43)	2 (8)	0	1(20)
Extrathyroidal extension, n (%)	8 (20)	1 (14)	4 (17)	0	3(60)
Lymphovascular invasion, n (%)	17 (43)	3 (43)	12 (50)	1(25)	1 (20)

pT, pathological T stage; pN, pathological N stage; pNX, no lymph node dissection.

Figure 1.

Representative histology of papillary thyroid carcinoma (PTC) subtypes. (a) Low-magnification image of cribriform variant of PTC. Follicular epithelial cells proliferated in cribriform patterns. Original magnification ×20. (b) High-magnification image of cribriform variant of PTC. Tumor cells showed distinct nuclear features, such as grooves and ground-glass appearance. Original magnification ×400. (c) Low-magnification image of poorly differentiated PTC with poorly differentiated components. The tumor contained papillary structures and poorly differentiated components, including solid and insular proliferations. The solid and insular components comprised about 20% of the tumor. Original magnification ×20. (d) High-magnification image of PTC with poorly differentiated components. The tumor cells of the poorly differentiated components showed no distinct nuclear features of PTC. Original magnification ×200. Hematoxylin and eosin staining.

BRAF V600E analysis

The BRAF V600E mutation status (Figure 2) and clinicopathological features of the included cases are listed in Table 3 and summarized in Table 4. In the pediatric cases (13–19 years), BRAF V600E was detected in one 17-year-old and one 18-year-old patient. The frequency of BRAF V600E mutation increased significantly with increasing age (P = 0.022).

Figure 2.

Representative sequence of exon 15 of the BRAF gene. Arrow shows heterozygous T to A mutation (a) and wild-type (b).

Table 3.

Clinicopathological features and BRAF V600E status in all patients with papillary thyroid carcinoma.

Case	Age (years)	Sex	Hashimoto disease	Non- thyroid malignancy	FHx of benign thyroid disease	FHx of non-thyroid malignancy	FHx of thyroid cancer	Tumor size (cm)	Histology	pT	pN	Ex	Ly/V	M	Follow-up (months)	BRAF V600E
1	13	F	−	−	−	−	−	7	Conv	3b	1b	1	+	0	12	WT
2	14	F	−	−	−	−	−	2	Conv with poorly differentiated component	2	X	0	−	0	20	WT
3	16	F	−	−	−	−	−	2.3	Cribriform variant	2	X	0	−	0	93	WT
4	17	F	−	−	+	−	−	1.8	Conv	1b	1a	0	+	0	19	MT
5	18	F	−	−	+	−	+	0.7	Conv	1a	X	0	−	0	24	MT
6	19	F	+	−	−	−	−	2.2	Conv	2	1a	0	+	0	24	WT
7	19	F	+	−	−	−	−	1	Conv	1b	1a	0	−	0	18	WT
8	20	F	−	−	−	−	−	0.6	Conv	1a	X	0	−	0	21	WT
9	20	F	−	−	−	−	−	1.1	Conv	1b	1a	0	−	0	47	WT
10	20	F	−	−	−	−	−	3.5	Conv	2	1b	0	+	0	29	WT
11	21	F	−	−	−	−	−	1.8	Conv	1b	1a	0	+	0	24	WT
12	21	F	−	−	−	−	−	4	Conv	3a	1b	0	+	1	19	WT
13	21	F	−	−	−	−	−	0.8	Conv	1a	0	0	−	0	32	WT
14	21	F	−	−	−	−	−	1.8	Conv	1b	1a	0	+	0	96	WT
15	22	F	+	−	+	−	−	0.3	Conv	1a	0	0	+	0	29	WT
16	22	F	+	−	−	−	+	0.8	Conv	1a	0	0	−	0	16	WT
17	23	F	+	−	−	−	−	3	Conv	2	X	0	−	0	39	MT
18	23	F	−	−	−	−	−	2.8	Conv	2	0	0	−	0	32	WT
19	23	F	+	−	−	−	−	1.5	Conv	3b	0	1	−	0	80	WT
20	24	F	−	−	−	−	−	1.1	Conv	1b	1a	0	+	0	26	MT
21	24	F	−	−	−	−	−	3	Conv	2	1b	0	+	0	3	MT
22	24	M	−	−	−	+	−	2.5	Conv	2	1b	0	+	0	68	MT
23	24	F	+	−	−	−	−	0.6	Conv	1a	1a	0	−	0	30	MT
24	24	F	−	−	−	−	−	2.3	Conv	3b	1a	1	−	0	25	MT
25	24	F	+	−	−	−	−	2.1	Conv	2	1a	0	+	0	34	WT
26	25	F	+	−	−	−	−	1.4	Conv	3b	1a	1	+	0	25	WT
27	26	F	−	−	−	−	−	0.5	Conv	1a	1a	0	−	0	59	WT
28	28	F	−	−	−	−	−	0.5	Conv	1a	0	0	−	0	13	MT
29	28	F	−	−	−	−	−	0.7	Conv	1a	0	0	−	0	4	WT
30	34	F	−	−	−	−	−	1.7	Conv	1b	0	0	+	0	15	MT
31	34	F	−	−	−	−	−	2	Conv	3b	1b	1	+	0	3	WT
32	43	F	+	−	−	−	−	2.2	Conv	2	1a	0	−	0	8	MT
33	49	M	−	+	−	−	−	0.6	Conv	1a	0	0	−	0	1	MT
34	54	M	−	+	−	−	−	1.5	Conv	1b	1a	0	+	0	12	WT
35	58	F	−	+	−	−	+	1.5	Conv	1b	1a	0	−	0	8	MT
36	61	F	−	+	−	+	−	1.4	Conv	1b	0	0	−	0	10	MT
37	67	F	+	−	−	−	−	1.4	Conv	4a	X	1	−	0	7	MT
38	68	F	−	−	−	−	−	2.2	Conv	3b	1a	1	−	0	8	MT
39	72	F	+	−	−	−	−	3.5	Conv	3b	1a	1	+	0	14	MT
40	79	F	−	+	+	−	−	3	Conv	2	1b	0	−	0	11	MT

F, female; M, male; FHx, family history; Conv, conventional type; pT, pathological T stage; Ex, extrathyroidal extension; pN, pathological N stage; Ly/V, lymphovascular invasion; M, clinical M stage; WT, wild-type; MT, mutant.

Table 4.

Summary of the BRAF V600E status and clinicopathological features in all patients with papillary thyroid carcinoma.

				Age group (years)
		Total		13–19		20–39		40–59		60–79
		n = 40		n = 7		n = 24		n = 4		n = 5
BRAF		−	+	−	+	−	+	−	+	−	+
n (%)		22 (55)	18 (45)	5 (71)	2 (29)	16 (67)	8 (33)	1 (25)	3 (75)	0	5 (100)
Mean age [range], years		23 [13–54]	41 [17–79]	16 [13–19]	18 [17–18]	26 [20–34]	24 [23–24]	54 [54]	50 [43–58]	−	69 [61–79]
Sex	M, n (%)	1 (3)	2 (5)	0	0	0	1 (4)	1 (25)	1 (25)	0	0
Sex	F, n (%)	21 (53)	16 (40)	5 (71)	2 (29)	16 (67)	7 (29)	0	2 (50)	0	5 (100)
Hashimoto disease, n (%)	−	15 (38)	13 (33)	3 (43)	2 (29)	11 (46)	6 (25)	1 (25)	2 (50)	0	3 (60)
Hashimoto disease, n (%)	+	7 (18)	5 (13)	2 (29)	0	5 (20)	2 (8)	0	1 (25)	0	2 (40)
Non-thyroid malignancy, n (%)	−	21 (53)	14 (35)	5 (71)	2 (29)	16 (67)	8 (33)	0	1 (25)	0	3 (60)
Non-thyroid malignancy, n (%)	+	1 (3)	4 (10)	0	0	0	0	1 (25)	2 (50)	0	2 (40)
Family history of non-thyroid malignancy, n (%)	−	22 (55)	16 (40)	5 (71)	2 (29)	16 (67)	7 (29)	1 (25)	3 (75)	0	4 (80)
Family history of non-thyroid malignancy, n (%)	+	0	2 (5)	0	0	0	1 (4)	0	0	0	1 (20)
Family history of thyroid carcinoma, n (%)	−	21 (53)	16 (40)	5 (71)	1 (14)	15 (63)	8 (33)	1 (25)	2 (50)	0	5 (100)
Family history of thyroid carcinoma, n (%)	+	1 (3)	2 (5)	0	1 (14)	1 (14)	0	0	1 (25)	0	0
Family history of benign thyroid disease, n (%)	−	21 (53)	15 (38)	5 (71)	0	15 (63)	8 (33)	1 (25)	3 (75)	0	4 (80)
Family history of benign thyroid disease, n (%)	+	1 (3)	3 (8)	0	2 (29)	1 (4)	0	0	0	0	1 (20)
Mean tumor size [range], cm		2 [0.5–7.0]	1.8 [0.5–3.5]	2.9 [1.0–7.0]	1.3 [0.7–1.8]	1.7 [0.5–3.5]	1.8 [0.6–3.0]	1.5	1.4 [0.6–2.2]	−	2.3 [1.4–3.5]
pT stage, n (%)	pT1a	6 (15)	4 (10)	0	1 (14)	6 (25)	2 (3)	0	1 (25)	0	0
	pT1b	5 (13)	5 (13)	1 (14)	1 (14)	3 (13)	2 (3)	1 (25)	1 (25)	0	1 (20)
	pT2	6 (15)	5 (13)	3 (43)	0	3 (13)	3 (13)	0	1 (25)	0	1 (20)
	pT3a	1 (3)	0	0	0	1 (4)	0	0	0	0	0
	pT3b	4 (10)	3 (8)	1 (14)	0	3 (13)	1 (4)	0	0	0	2 (40)
	pT4a	0	1 (3)	0	0	0	0	0	0	0	1 (20)
pN stage, n (%)	pN0	6 (15)	4 (10)	0	0	6 (25)	2 (3)	0	1 (25)	0	1 (20)
	pN1a	9 (23)	8 (20)	2 (29)	1 (14)	6 (25)	3 (13)	1 (25)	2 (50)	0	2 (40)
	pN1b	4 (10)	3 (8)	1 (14)	0	3 (13)	2 (3)	0	0	0	1 (20)
	pNX	3 (8)	3 (8)	2 (29)	1 (14)	1 (4)	1 (4)	0	0	0	1 (20)
Extrathyroidal extension, n (%)	−	18 (45)	14 (35)	4 (57)	2 (29)	13 (54)	7 (29)	1 (25)	3 (75)	0	2 (40)
Extrathyroidal extension, n (%)	+	4 (10)	4 (10)	1 (14)	0	3 (13)	1 (4)	0	0	0	3 (60)
Lymphovascular invasion, n (%)	−	11 (28)	12 (30)	3 (43)	1 (14)	8 (33)	4 (17)	0	3 (75)	0	4
Lymphovascular invasion, n (%)	+	11 (28)	6 (15)	2 (29)	1 (14)	8 (33)	4 (17)	1 (25)	0	0	1 (20)

pT, pathological T stage; pN, pathological N stage; M, male; F, female; pNX, no lymph node dissection.

There were no significant associations between mutational status and other clinicopathological features including sex, Hashimoto disease, family history of thyroid disease, tumor size, pathological T stage, pathological N stage, lymphovascular invasion, extrathyroidal extension, and metastasis

Discussion

The aim of this study was to investigate the frequencies of BRAF mutation in adult and pediatric patients with PTC, and to clarify the relationships between mutation status and clinicopathological features in our institution. BRAF V600E mutation occurred in 45% of patients overall and in 29% of pediatric cases (two patients aged 17 and 18 years, respectively). The frequency of BRAF V600E mutation increased significantly with age, but no other clinicopathological characteristics were associated with BRAF V600E mutation status.

The reported incidence of BRAF V600E mutation has ranged from 36% to 83%,⁴ with a higher prevalence in Asian countries, including Japan and Korea, compared with western countries²⁶ associated with differences in iodine intake.²⁷ The overall frequency of BRAF V600E in the present study was within the reported range, but relatively low for an Asian population. There are several possible explanations for this apparent discrepancy. First, 60% of the cases analyzed in the current study were in their second and third decades, and this age distribution might have affected findings. Second, we detected the mutation by Sanger sequencing using FFPE tissues. Sanger sequencing with FFPE^28,29 or frozen tissues and real-time PCR are currently the main methods used, though droplet digital PCR (ddPCR) and next-generation sequencing have also been used to assess genetic profiles.^30,31 The sensitivity for detecting the mutation is increased by manual tissue dissection because this is more effective at excluding normal tissues in which the occurrence of the single nucleotide polymorphism is negligible. Sanger sequencing has been reported to be more sensitive for detecting BRAF V600E than real-time PCR, but less sensitive than ddPCR.^30,32 We therefore used manually dissected FFPE samples and Sanger sequencing as a cost-effective way of detecting the BRAF V600E mutation in surgical specimens. Nasirden et al.²⁹ reported BRAF V600E in 38% of Japanese PTC patients using FFPE samples and Sanger sequencing, with a similar population, methodology, and mutation frequency to our current study. The geographic background of the patients and the methodology may thus be key factors affecting the frequency of the BRAF V600E mutation. Kowalska et al.³³ demonstrated time-dependent trends in the prevalence of this mutation in PTC, with significant increases in its prevalence during 2000 to 2004, 2005 to 2009, and 2010 to 2013. Further investigations of the relationships between BRAF V600E frequency and the clinicopathological features of PTC should thus take account of different time periods and regions.

The current results indicated that the frequency of the BRAF V600E mutation increased with increasing age in patients with PTC, in line with previous reports.¹⁵ However, few reports have investigated the influence of age on mutation incidence. A review of previous publications regarding the incidence of BRAF V600E mutation in relation to median age showed that it occurred in 49% of 45-year olds³⁴63% of 47-year olds,³⁵ and 85% of 58-year olds.⁵ One recent study also demonstrated a positive correlation between BRAF V600E and age. Patients were divided into age groups and the BRAF V600E mutation was found in approximately 55%, 80%, 85%, 88%, and 90% of patients aged < 25 years, 25 to 35, 35 to 45, 45 to 55, and >55 years old, respectively.³⁶ This trend was also seen in patients with colorectal cancer.³⁷ In a study investigating the relationship between age and driver mutations, Yokoyama et al.³⁸ demonstrated that remodeling of the esophageal epithelium by numerous driver-mutated clones was an inevitable consequence of normal aging. It is therefore plausible that the frequency of the BRAF V600E mutation might be higher in older PTC patients.

Regarding the pediatric population, previous studies^1,5–11 have reported the BRAF V600E mutation in 0% to 63% of pediatric PTC patients (Table 5). Although the results varied, a higher rate of BRAF mutation reflected an older age distribution of the analyzed cases, particularly showing a higher frequency in patients above 15 years of age. BRAF mutation was detected in two of the pediatric cases in the present study, both of whom were over 15 years old.

Table 5.

Previous studies on BRAF V600E mutation frequency in pediatric patients with papillary thyroid carcinoma.

Reference	Age (years)	Population	BRAF mutation
Penko et al.⁶	10–21	USA	0
Penko et al.⁶	(mean 17.5 ± 3.5)
Rosenbaum et al.⁷	10–17	USA	5%
Rosenbaum et al.⁷	(mean 15)
Kumagai et al.⁸	Mean 11	Japan	3.2%
	<15	Ukraine	24%
	(mean 18.6)	Ukraine
Givens et al.⁹	2–18	USA	36.8%
Givens et al.⁹	(mean 13.6)		(Conventional type PTC 63%)
Mostoufi-Moab et al.¹⁰	<18	USA	44%
Oishi et al.⁵	6–20	Japan	54%
Oishi et al.⁵	(17.4 ± 2.7)
Henke et al.¹¹	5.8–21.2	USA	63%
Henke et al.¹¹	(mean 18.6)

PTC, papillary thyroidcarcinoma.

Genetic alterations detected in PTCs include BRAF V600E, RAS, RET/PTC rearrangement, and ETV6-NTRK, of which BRAF V600E is the most common. BRAF mutation stimulates the MAPK pathway, resulting in cell growth, proliferation, and differentiation.³⁹ Accumulated studies have demonstrated associations between BRAF V600E and some clinicopathological characteristics of PTC, including aggressive features. PTC with BRAF mutation was shown to occur in patients in their 50s¹⁵ and predominantly in males.^12–14 BRAF-mutated tumors also tend to be large,^13,16–18 with conventional tumor histology,³⁴ and extrathyroidal extension,^15,18,19 vascular invasion,^12,20 and lymph node metastasis^5,12,20 were also frequently observed. The pathological stage is usually advanced,^18,19,21 and recurrence was noted in 25% of patients.¹⁷ The prognosis in patients with PTC and BRAF mutation is generally unfavorable, and disease-specific mortality is higher than in BRAF-mutation-negative cases.^5,22 However, some reports have shown the opposite results or no association, and these apparent differences may be attributable to differences between the studies in terms of patient background, including factors such as race, iodine intake, radiation, family history, methodology, or sampling.²² Mitsutake et al.²³ found that BRAF V600E-mutated PTC was not associated with aggressive features in an Asian population, which was in accord with the present study also conducted in Asian patients. These results suggest that BRAF V600E is not a marker of tumor aggressiveness in Asian patients with PTC, but may have a positive predictive value for diagnosing thyroid tumors.

This study was conducted in a single institution and had several limitations. First, our study involved a limited number of PTC cases and could therefore not thoroughly reflect the general population. Second, the analyzed patients were predominantly female. Our institution employs video-assisted neck surgery for the resection of thyroid tumors,⁴⁰ which is a safe and practical method with cosmetic benefits leading to a predominance of female patients, with a male:female ratio of approximately 1:3. The number of male patients in this study may therefore have been too small to allow the evaluation of any association between BRAF mutation and sex. Third, few included cases had tumors <1 cm. Clinically, our institution prefers to carry out active surveillance as an alternative to immediate surgery in patients with very low-risk PTC, in accord with the strategy officially approved by the 2015 American Thyroid Association guidelines.⁴¹ The number of surgical specimens of microcarcinomas, representing very low-risk PTC, was therefore limited during the study period. However, although our sample had a bias in term of tumor size, the clinical features were nonetheless of practical value given that active surveillance is standard in clinical practice.

In conclusion, our results showed that 45% of PTCs had BRAF mutations, which was within the previously reported range, and that the frequency of these mutations increased significantly with increasing age. Genetic alterations can inform the prognosis, therapy, follow-up, and molecular targeted therapy of PTC, highlighting the need to clarify the genetic profile of these patients, including in terms of BRAF mutation status. However, the genetic profiles should take account of population data and time periods. Despite the limited number of cases, the results of the current study may contribute to the genetic profile of PTC in Asian populations.

Footnotes

Acknowledgements

The authors thank Kiyoko Kawahara, Takenori Fujii, Kiyoshi Teduka, Yoko Kawamoto, and Taeko Kitamura for their skillful assistance.

Declaration of conflicting interest

The authors declare that there is no conflict of interest.

Funding

This study was funded by the Japanese Association of University Women [the 66^th Homes Scholarship, 2014]; and the Children’s Cancer Association of Japan [2017–2019]. The funding sources had no role in the design of the study, the collection, analysis, and interpretation of the data, or in the writing of the manuscript.

References

Vanden Borre

Schrock

Anderson

, et al. Pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions. Oncologist 2017; 22: 255–263.

Xing

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.

Endocr Rev 2007; 28: 742–762.

Lupi

Giannini

Ugolini

, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 4085–4090.

Tavares

Melo

Cameselle-Teijeiro

, et al. Endocrine tumours: genetic predictors of thyroid cancer outcome. Eur J Endocrinol 2016; 174: R117–R126.

Oishi

Kondo

Nakazawa

, et al. Frequent BRAF V600E and absence of TERT promoter mutations characterize sporadic pediatric papillary thyroid carcinomas in Japan. Endocr Pathol 2017; 28: 103–111.

Penko

Livezey

Fenton

, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005; 15: 320–325.

Rosenbaum

Hosler

Zahurak

, et al. Mutational activation of BRAF is not a major event in sporadic childhood papillary thyroid carcinoma. Mod Pathol 2005; 18: 898–902.

Kumagai

Namba

Saenko

, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 4280–4284.

Givens

Buchmann

Agarwal

, et al. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 2014; 124: E389–E393.

10.

Mostoufi-Moab

Labourier

Sullivan

, et al. Molecular testing for oncogenic gene alterations in pediatric thyroid lesions. Thyroid 2018; 28: 60–67.

11.

Henke

Perkins

Pfeifer

, et al. BRAF V600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 2014; 61: 1168–1172.

12.

Xing

Liu

, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol 2014; 32: 2718–2726.

13.

Kim

Rhee

, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364–368.

14.

Quiros

Gattuso

, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003; 63: 4561–4567.

15.

Nikiforova

Kimura

Gandhi

, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399–5404.

16.

Oler

Cerutti

JM.

High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.

Cancer 2009; 115: 972–980.

17.

Elisei

Ugolini

Viola

, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008; 93: 3943–3949.

18.

Yang

Sun

Jiang

, et al. The clinicopathological features of BRAF mutated papillary thyroid cancers in Chinese patients. Int J Endocrinol 2015; 2015: 642046.

19.

Xing

Westra

Tufano

, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005; 90: 6373–6379.

20.

Picarsic

Buryk

Ozolek

, et al. Molecular characterization of sporadic pediatric thyroid carcinoma with the DNA/RNA ThyroSeq v2 next-generation sequencing assay. Pediatr Dev Pathol 2016; 19: 115–122.

21.

Riesco-Eizaguirre

Gutierrez-Martinez

Garcia-Cabezas

, et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006; 13: 257–269.

22.

Penna

Vaisman

, et al. Molecular markers involved in tumorigenesis of thyroid carcinoma: focus on aggressive histotypes. Cytogenet Genome Res 2016; 150: 194–207.

23.

Mitsutake

Fukushima

Matsuse

, et al. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl. Sci Rep 2015; 5: 16976.

24.

Chindris

Casler

Bernet

, et al. Clinical and molecular features of Hurthle cell carcinoma of the thyroid. J Clin Endocrinol Metab 2015; 100: 55–62.

25.

Cicenas

Tamosaitis

Kvederaviciute

, et al. KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma. Med Oncol 2017; 34: 26.

26.

Lee

Hwang

Choi

, et al. Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAF(V600E) mutation. Thyroid 2017; 27: 802–810.

27.

Kim

Park

Byun

, et al. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area. Eur J Nutr 2018; 57: 809–815.

28.

Malaguarnera

Chen

Kim

, et al. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines. J Clin Endocrinol Metab 2014; 99: E1976–E1987.

29.

Nasirden

Saito

Fukumura

, et al. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Archiv 2016; 469: 687–696.

30.

Bartolome

Boskovic

Paunovic

, et al. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation. APMIS 2016; 124: 271–277.

31.

Bandoh

Akahane

Goto

, et al. Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution’s experience. Oncol Lett 2018; 16: 7278–7286.

32.

Malicherova

Burjanivova

Grendar

, et al. Droplet digital PCR for detection of BRAF V600E mutation in formalin-fixed, paraffin-embedded melanoma tissues: a comparison with Cobas((R)) 4800, Sanger sequencing, and allele-specific PCR. Am J Transl Res 2018; 10: 3773–3781.

33.

Kowalska

Walczyk

Kowalik

, et al. Increase in papillary thyroid cancer incidence is accompanied by changes in the frequency of the BRAF V600E mutation: a single-institution study. Thyroid 2016; 26: 543–551.

34.

Xing

Alzahrani

Carson

, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015; 33: 42–50.

35.

Jin

Chen

Dong

, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget 2016; 7: 18346–18355.

36.

Yan

Huang

, et al. Relationship between BRAFV600E and clinical features in papillary thyroid carcinoma. Endocr Connect 2019. Epub ahead of print. DOI: 10.1530/EC-19-0246.

37.

Lam

AK.

BRAF mutation: Current and future clinical pathological applications in colorectal carcinoma. Histol Histopathol 2018. Epub ahead of print. DOI: 10.14670/HH-18-079. 18079

38.

Yokoyama

Kakiuchi

Yoshizato

, et al. Age-related remodelling of oesophageal epithelia by mutated cancer drivers. Nature 2019; 565: 312–317.

39.

Kure

Wada

Naito

Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma. Med Mol Morphol 2019. Epub ahead of print 2019/02/23. DOI: 10.1007/s00795-019-00217-6.

40.

Shimizu

Akira

Tanaka

Video-assisted neck surgery: endoscopic resection of benign thyroid tumor aiming at scarless surgery on the neck.

J Surg Oncol 1998; 69: 178–180.

41.

Sakai

Sugitani

Ebina

, et al. Active surveillance for T1bN0M0 papillary thyroid carcinoma. Thyroid 2018. Epub ahead of print. DOI: 10.1089/thy.2018.0462.

Incidence of BRAF V600E mutation in patients with papillary thyroid carcinoma: a single-institution experience

Abstract

Objective

Methods

Results

Conclusions

Keywords

Introduction

Methods

Patients

Genetic analysis

Statistical analysis

Results

Clinical characteristics

Disease characteristics

BRAF V600E analysis

Discussion

Footnotes

Acknowledgements

Declaration of conflicting interest

Funding

References